AGOMELATINE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $13,442 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,442 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN 8 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF AGOMELATINE HALF A MG AND 1 MG SUBLINGUAL TABLETS ADMINISTERED ONCE DAILY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD | Novartis Pharmaceuticals Corporation | $13,442 | 0 |
Top Doctors Receiving Payments for AGOMELATINE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Atlanta, GA | $13,442 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $13,442
- Total Doctors 0
- Transactions 1
About AGOMELATINE
AGOMELATINE is a drug associated with $13,442 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2017. In 2017, $13,442 was paid across 1 transactions to 0 doctors.
The most common payment nature for AGOMELATINE is "Unspecified" ($13,442, 100.0% of total).
AGOMELATINE is associated with 1 research study, including "AN 8 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF AGOMELATINE HALF A MG AND 1 MG SUBLINGUAL TABLETS ADMINISTERED ONCE DAILY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER MDD" ($13,442).